Diplomat Pharmacy Inc (NYSE:DPLO) Expected to Announce Earnings of -$0.19 Per Share

Wall Street analysts expect Diplomat Pharmacy Inc (NYSE:DPLO) to report earnings per share of ($0.19) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Diplomat Pharmacy’s earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.22). Diplomat Pharmacy posted earnings of $0.14 per share in the same quarter last year, which would suggest a negative year over year growth rate of 235.7%. The business is scheduled to announce its next earnings report on Friday, March 20th.

According to Zacks, analysts expect that Diplomat Pharmacy will report full year earnings of ($4.87) per share for the current fiscal year, with EPS estimates ranging from ($4.90) to ($4.83). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.62) per share, with EPS estimates ranging from ($1.04) to ($0.39). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Diplomat Pharmacy.

Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($2.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($2.15). Diplomat Pharmacy had a negative return on equity of 12.15% and a negative net margin of 12.47%. The firm had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.17 billion. The company’s revenue for the quarter was down 5.3% compared to the same quarter last year.

A number of equities research analysts have recently issued reports on DPLO shares. Zacks Investment Research lowered shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Friday, November 15th. Deutsche Bank began coverage on shares of Diplomat Pharmacy in a research note on Thursday, September 12th. They issued a “sell” rating and a $4.00 price target on the stock. Raymond James lowered shares of Diplomat Pharmacy from an “outperform” rating to a “market perform” rating in a research report on Monday. Wells Fargo & Co upped their price objective on shares of Diplomat Pharmacy from $5.00 to $5.50 and gave the company a “market perform” rating in a research note on Tuesday, August 13th. Finally, ValuEngine downgraded shares of Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 5th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $8.69.

DPLO traded up $0.03 on Thursday, hitting $3.94. 5,275,419 shares of the company’s stock were exchanged, compared to its average volume of 1,183,045. Diplomat Pharmacy has a fifty-two week low of $2.43 and a fifty-two week high of $15.32. The company has a current ratio of 0.55, a quick ratio of 0.36 and a debt-to-equity ratio of 0.18. The firm has a 50-day moving average price of $4.98 and a 200-day moving average price of $5.23. The stock has a market cap of $297.04 million, a price-to-earnings ratio of 19.70 and a beta of 0.92.

A number of institutional investors have recently added to or reduced their stakes in the stock. Stephens Inc. AR lifted its position in Diplomat Pharmacy by 1,482.3% in the second quarter. Stephens Inc. AR now owns 6,600,015 shares of the company’s stock valued at $40,194,000 after buying an additional 6,182,889 shares during the last quarter. Millennium Management LLC purchased a new stake in Diplomat Pharmacy during the 3rd quarter worth about $7,073,000. JPMorgan Chase & Co. raised its position in Diplomat Pharmacy by 390.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,445,834 shares of the company’s stock valued at $8,632,000 after purchasing an additional 1,150,740 shares in the last quarter. BlackRock Inc. raised its position in Diplomat Pharmacy by 7.2% in the 2nd quarter. BlackRock Inc. now owns 9,154,249 shares of the company’s stock valued at $55,749,000 after purchasing an additional 614,918 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Diplomat Pharmacy by 53.4% in the 2nd quarter. Invesco Ltd. now owns 1,220,554 shares of the company’s stock valued at $7,433,000 after buying an additional 424,647 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Article: Buy Rating

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.